NCT00977561

A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer

A Phase 2, Randomized, Open Label Study Of Figitumumab (CP-751,871) Plus Cisplatin (Or Carboplatin) And Etoposide, Versus Cisplatin (Or Carboplatin) And Etoposide Alone, As First Line Treatment In Patients With Extensive Stage Disease Small Cell Lung Cancer

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will summarize the safety of patients receiving figitumumab combined with etoposide and cisplatin (or carboplatin) vs. patients receiving etoposide and cisplatin (or carboplatin) alone as first line treatment for extensive stage disease Small Cell Lung Cancer.

Detailed description

The study prematurely discontinued on January 26, 2011 due to slow enrollment. It should be noted that safety concerns have not been seen in this study and have not factored into this decision.

Conditions

• Small Cell Lung Carcinoma

Interventions

Type	Name	Description
DRUG	figitumumab	Figitumumab (20 mg/kg)
DRUG	Cisplatin (Or Carboplatin)	Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5
DRUG	Etoposide	Etoposide (100 mg/m2 IV on Days 1, 2 and 3)
DRUG	Cisplatin (Or Carboplatin)	Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5
DRUG	Etoposide	Etoposide (100 mg/m2 IV on Days 1, 2 and 3)

Timeline

• Start date: 2010-04-01
• Primary completion: 2011-10-01
• Completion: 2011-10-01
• First posted: 2009-09-15
• Last updated: 2013-02-25
• Results posted: 2013-02-25

Locations

51 sites across 4 countries: United States, Canada, Hungary, Spain